ArticleBMJ medicine2025

Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration's accelerated approval pathway: retrospective observational study and economic evaluation.

Huseyin Naci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.